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Abstract
BACKGROUND: Smoking is the leading preventable cause of premature death in the United States. Previous
studies of financial incentives for smoking cessation in work settings have not shown that such incentives have
significant effects on cessation rates, but these studies have had limited power, and the incentives used may
have been insufficient.
METHODS: We randomly assigned 878 employees of a multinational company based in the United States to
receive information about smoking-cessation programs (442 employees) or to receive information about
programs plus financial incentives (436 employees). The financial incentives were $100 for completion of a
smoking-cessation program, $250 for cessation of smoking within 6 months after study enrollment, as
confirmed by a biochemical test, and $400 for abstinence for an additional 6 months after the initial cessation,
as confirmed by a biochemical test. Individual participants were stratified according to work site, heavy or
nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after
enrollment, depending on whether initial cessation was reported at 3 or 6 months. Secondary end points were
smoking cessation within the first 6 months after enrollment and rates of participation in and completion of
smoking-cessation programs.
RESULTS: The incentive group had significantly higher rates of smoking cessation than did the information-
only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P
CONCLUSIONS: In this study of employees of one large company, financial incentives for smoking cessation
significantly increased the rates of smoking cessation. (ClinicalTrials.gov number, NCT00128375.)
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a bs tr ac t
Background
Smoking is the leading preventable cause of premature death in the United States. 
Previous studies of financial incentives for smoking cessation in work settings have 
not shown that such incentives have significant effects on cessation rates, but these 
studies have had limited power, and the incentives used may have been insufficient.
Methods
We randomly assigned 878 employees of a multinational company based in the Unit-
ed States to receive information about smoking-cessation programs (442 employees) 
or to receive information about programs plus financial incentives (436 employees). 
The financial incentives were $100 for completion of a smoking-cessation program, 
$250 for cessation of smoking within 6 months after study enrollment, as confirmed 
by a biochemical test, and $400 for abstinence for an additional 6 months after the 
initial cessation, as confirmed by a biochemical test. Individual participants were 
stratified according to work site, heavy or nonheavy smoking, and income. The pri-
mary end point was smoking cessation 9 or 12 months after enrollment, depending 
on whether initial cessation was reported at 3 or 6 months. Secondary end points 
were smoking cessation within the first 6 months after enrollment and rates of par-
ticipation in and completion of smoking-cessation programs.
Results
The incentive group had significantly higher rates of smoking cessation than did 
the information-only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P<0.001) 
and 15 or 18 months after enrollment (9.4% vs. 3.6%, P<0.001). Incentive-group par-
ticipants also had significantly higher rates of enrollment in a smoking-cessation 
program (15.4% vs. 5.4%, P<0.001), completion of a smoking-cessation program (10.8% 
vs. 2.5%, P<0.001), and smoking cessation within the first 6 months after enroll-
ment (20.9% vs. 11.8%, P<0.001).
Conclusions
In this study of employees of one large company, financial incentives for smoking 
cessation significantly increased the rates of smoking cessation. (ClinicalTrials.gov 
number, NCT00128375.)
The New England Journal of Medicine 
Downloaded from nejm.org on June 2, 2016. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;7 nejm.org february 12, 2009700
Smoking remains the leading pre-ventable cause of premature death in the United States, accounting for approximately 
438,000 deaths each year.1 Seventy percent of 
smokers report that they want to quit,2 but annu-
ally only 2 to 3% of smokers succeed.3,4 Although 
smoking-cessation programs and pharmacologic 
therapies have been associated with higher rates 
of cessation, rates of participation in such pro-
grams and use of such therapies are low.5,6
Work sites offer a promising venue for encour-
aging smoking cessation because employers are 
likely to bear many of the excess health care costs 
and productivity losses that are due to missed 
work among smokers. In addition, existing chan-
nels of communication can be used to reach smok-
ers and reinforce healthful behavior choices. Previ-
ous studies have shown that providing smokers 
with financial incentives to stop smoking increas-
es enrollment in smoking-cessation programs and 
short-term cessation rates,7-10 but the studies have 
not shown significant increases in long-term ces-
sation rates. Similarly, studies of financial-incentive 
programs in work settings have not shown sig-
nificant differences in long-term cessation rates,11 
though the studies generally were limited by small 
sample sizes and weak financial incentives.
In this randomized, controlled trial involving 
employees at a large, multinational company based 
in the United States, we tested the effectiveness 
of a financial incentive of up to $750 in improving 
long-term rates of smoking cessation.
Me thods
Study Population
We recruited study participants from February 
2005 through November 2006 among employees 
at company work sites throughout the United 
States. Potential participants were identified with 
the use of a survey that asked employees about 
their smoking habits, their use of other tobacco 
products, and their willingness to be contacted by 
researchers from the University of Pennsylvania 
about participation in a smoking-cessation study. 
These surveys were distributed through the firm’s 
intranet and, at sites with high proportions of em-
ployees who did not have intranet access, through 
on-site recruiting. Employees were eligible to par-
ticipate if they were at least 18 years of age and if 
they reported that they were currently smoking 
five or more cigarettes per day. Employees were 
not included in the study if they were currently 
using tobacco products other than cigarettes or if 
they planned to leave the firm within 18 months. 
All participants were followed for at least 12 
months; only those with a confirmed negative re-
sult within the first 12 months on a cotinine test, 
a test that is used for biochemical verification of 
self-reported abstinence, were followed for an ad-
ditional 6 months.
Study Protocol
The protocol was approved by the institutional re-
view board at the University of Pennsylvania, and 
all participants provided written informed consent 
before randomization. All study participants re-
ceived information about community-based smok-
ing-cessation resources within 20 miles of their 
work site, as well as the standard health benefits 
provided by the firm, such as coverage of physi-
cian visits and bupropion or other drugs pre-
scribed to promote cessation of tobacco use. Par-
ticipants in the incentive group were also informed 
that they would receive financial incentives for 
completion of a community-based smoking-ces-
sation program ($100); for smoking cessation, 
confirmed with the use of a cotinine test, within 
6 months after study enrollment ($250); and for 
continued abstinence for an additional 6 months 
after the initial cessation ($400).
All participants were contacted 3 months after 
enrollment and asked whether they had stopped 
smoking. Participants who reported complete ab-
stinence (not even a puff of a cigarette) for at least 
7 days before being contacted were interviewed 
so that we could obtain a more extensive assess-
ment of smoking behavior. Participants who did 
not report complete abstinence were recontacted 
3 months later (i.e., 6 months after enrollment) 
for the full follow-up assessment. Six months 
after completing their first full interview (i.e., 
at 9 months for those who reported quitting at 
3 months; at 12 months for those who were inter-
viewed at 6 months), everyone was interviewed 
again. Participants who reported during any fol-
low-up interview that they had stopped smoking 
were asked to provide a saliva or urine sample for 
confirmation of smoking cessation with the use 
of a cotinine test. Participants with negative results 
of cotinine tests at both the interview conducted 
at 3 or 6 months and the interview conducted at 
The New England Journal of Medicine 
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9 or 12 months were also interviewed 12 months 
after completion of their initial full interview (i.e., 
at 15 or 18 months).
Participants received $20 per interview for par-
ticipating in telephone interviews at baseline, at 
3 or 6 months, at 9 or 12 months, and at 15 or 18 
months. After each interview, participants who 
reported that they had stopped smoking received 
$25 for submitting a sample for biochemical veri-
fication of the cotinine level.
Randomization Procedures
Participants were randomly assigned to a study 
group after they provided informed consent. Ran-
domization was performed in permuted blocks 
of four and was stratified according to work site, 
income (<200%, 200 to 500%, or >500% of the 
federal poverty level, which was $9,800 for a sin-
gle person and $20,000 for a family of four in 
2006), and heavy or nonheavy smoking (with heavy 
smoking defined as two or more packs of ciga-
rettes per day). The randomized assignments were 
concealed until all eligibility criteria had been 
entered in an electronic tracking system; howev-
er, blinding could not be maintained after this 
point because of the nature of the intervention.
Assessments of End Points
The primary end point was the participant’s self-
report of abstinence at both 3 and 9 months or at 
both 6 and 12 months after study enrollment. 
Abstinence was biochemically confirmed by a neg-
ative result of a cotinine test performed on a sa-
liva or urine sample. Self-reported continuous ab-
stinence from all tobacco products was defined 
as abstinence for a minimum of 7 days before the 
3- or 6-month interview (point prevalence) and 
abstinence for the duration of the period from 
the 3- or 6-month interview to the 9- or 12-month 
interview (prevalence of prolonged abstinence).
Secondary end points included enrollment in 
a smoking-cessation program; completion of a 
smoking-cessation program; rates of smoking ces-
sation within 6 months after study enrollment; 
and rates of smoking cessation at 3, 9, and 15 
months or 6, 12, and 18 months after study en-
rollment. Participants were classified as having 
completed the smoking-cessation program if they 
provided a certificate of completion from the 
sponsoring organization.
All follow-up assessments were conducted with 
Table 1. Characteristics of the Study Participants.*
Characteristic
Control Group 
(N = 442)
Incentive Group 
(N = 436)
Mean age (yr) 44.4 45.5
Male sex (%) 64.9 65.6
Race or ethnic group (%)†
White 89.3 91.5
Black 5.2 4.4
Hispanic 4.1 4.1
Other 5.4 4.1
Level of education (%)
High school or lower 25.6 25.2
Some college or completion of college 39.6 40.8
Beyond college 34.8 33.9
Income (%)
<200% of the poverty level 1.6 1.8
200–500% of the poverty level 34.6 32.1
>500% of the poverty level 63.8 66.1
Smoking habits
Mean cigarettes per day (no.) 19.7 20.1
Smoking >2 packs per day (%) 6.1 5.1
Mean previous attempts to quit (no.) 6.7 5.7
Stage of change (%)‡
Precontemplation 15.6 15.1
Contemplation 63.8 67.0
Preparation 20.6 17.9
Self-assessed health (%)
Poor 2.0 1.2
Fair 9.3 8.5
Good 32.1 33.7
Very good 45.9 42.7
Excellent 10.6 14.0
Fagerström score for nicotine  dependence 
(%)§
<6 68.1 66.5
≥6 31.9 33.5
* There were no significant differences between the control and incentive 
groups for any of the variables listed.
† Race or ethnic group was self-reported. One participant in the control group 
did not report race or ethnic group and therefore was not included in the de-
nominator for the percentages.
‡ Stage of change refers to the smoker’s readiness, at baseline, to quit, as de-
fined by DiClemente et al.16 and Prochaska et al.17
§ The Fagerström Test for Nicotine Dependence14 has a range of 0 to 10, with 
higher scores indicating more nicotine dependence; a score of 6 or greater 
was used to classify participants as highly dependent on nicotine.15
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the use of a telephone interview. Self-reported ces-
sation was verified by saliva cotinine tests (with 
a cotinine level of <15 ng per milliliter considered 
to be an indication of smoking cessation)12 or by 
urine cotinine tests (with a level of <2 ng per mil-
liliter considered to be an indication of smoking 
cessation).13 Urine cotinine tests were used only 
in the case of participants who were using nico-
tine-replacement therapy, in whom testing of anab-
asine and anatabine levels in the urine was per-
formed. Participants who reported abstinence but 
who had saliva or urine cotinine levels above the 
cutoff points were classified as smokers. Partici-
pants who were lost to follow-up were classified 
as relapsed smokers.
The collection of samples was coordinated by 
the study staff in conjunction with the health-
promotion staff at the firm and, at small work 
sites that did not have onsite health facilities, 
through contract with Examination Management 
Services (Scottsdale, AZ). Participants’ identities 
were confirmed and samples were analyzed at the 
Clinical Pharmacology Laboratory at the Univer-
sity of California, San Francisco.
Baseline Variables
The pretreatment level of nicotine dependence was 
assessed according to the number of cigarettes 
smoked per day, the number of years of smoking, 
and the score on the Fagerström Test for Nico-
tine Dependence14 (which has a range of 0 to 10, 
with higher scores indicating more nicotine de-
pendence); participants with a score of 6 or greater 
were classified as highly dependent on nicotine.15 
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Figure 1. Assessment for Eligibility, Randomization, and Follow-up.
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We also collected information on income, work 
site, baseline health status, and interest in quit-
ting, as measured by baseline readiness to stop 
smoking (i.e., the “stage of change,” as defined by 
DiClemente et al.16 and Prochaska et al.17). 
Statistical Analysis
The primary analysis was an unadjusted intention-
to-treat analysis of the difference in biochemically 
confirmed cessation rates between the incentive 
and control groups at both 3 and 9 months or at 
both 6 and 12 months. The analysis was performed 
with the use of Pearson’s chi-square test, or with 
the use of Fisher’s exact test, if there were five or 
fewer participants per cell. We used a similar ap-
proach to estimate differences in rates of cessa-
tion within 6 months after enrollment; rates of 
enrollment in and completion of smoking-cessa-
tion programs; and cessation rates at 3, 9, and 15 
months or 6, 12, and 18 months after study en-
rollment. Unadjusted odds ratios for cessation were 
estimated and were compared with odds ratios 
that were adjusted for the stratification variables 
(work site, degree of nicotine dependence, and in-
come) as well as the set of baseline covariates 
shown in Table 1; variable-selection methods were 
not applied. The similarity of the study groups with 
respect to covariates at baseline was analyzed by 
the chi-square test for categorical variables and 
the Student’s t-test or Wilcoxon rank-sum test for 
continuous variables, as appropriate.
Although subgroup analyses were not prespeci-
Table 2. Smoking-Cessation End Points According to Group Assignment.*
End Point 
Control Group 
(N = 442)
Incentive Group 
(N = 436) P Value
no. (%)
Enrollment in smoking-cessation program 
Participation in program 24 (5.4) 67 (15.4) <0.001
Completion of program 11 (2.5) 47 (10.8) <0.001
Smoking cessation at 3 or 6 mo
Self-reported 62 (14.0) 102 (23.4) <0.001
Confirmed 52 (11.8) 91 (20.9) <0.001
No sample submitted 9 (2.0) 9 (2.1) 0.79
Positive sample submitted 1 (0.2) 2 (0.5) 0.56
Smoking cessation at 3 or 6 mo with continued abstinence 
through 9 or 12 mo
Self-reported 27 (6.1) 66 (15.1) 0.002
Confirmed 22 (5.0) 64 (14.7) <0.001
No sample submitted 5 (1.1) 2 (0.5) 0.06
Positive sample submitted 0 0
Self-reported relapse 21 (4.8) 21 (4.8) 0.96
Continued abstinence at 15 or 18 mo among participants  
who quit at 3 or 6 mo and remained abstinent  
through 9 or 12 mo
Self-reported 17 (3.8) 47 (10.8) <0.001
Confirmed 16 (3.6) 41 (9.4) <0.001
No sample submitted 1 (0.2) 6 (1.4) 0.03
Positive sample submitted 0 0 
Self-reported relapse 3 (0.7) 12 (2.8) 0.02
* Smoking cessation was confirmed by means of a negative result on a cotinine test.
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Table 3. Odds Ratios for Long-Term (9- or 12-Month) Smoking Cessation.
Variable Odds Ratio (95% CI) P Value
Unadjusted model
Incentive group 3.28 (1.98–5.44) <0.001
Control group 1.00
Model adjusted for stratification variables only
Study group <0.001
Incentive 3.19 (1.91–5.30)
Control 1.00
Work site* 0.12
Smoking status† 0.15
Heavy 0.34 (0.08–1.45)
Nonheavy 1.00
Poverty level 0.02
>500% of the poverty level 0.96 (0.20–4.63)
200–500% of the poverty level 0.43 (0.08–2.16)
<200% of the poverty level 1.00
Model adjusted for all variables‡
Study group <0.001
Incentive 3.16 (1.88–5.32)
Control 1.00
Work site* 0.20
Age 0.87
≥40 yr 1.05 (0.58–1.90)
<40 yr 1.00
Sex 0.39
Male 0.80 (0.48–1.33)
Female 1.00
Race 0.69
Black 1.02 (0.32–3.20)
White 1.00
Other 0.50 (0.10–2.44)
Ethnic group 0.80
Hispanic 1.20 (0.30–4.88)
Non-Hispanic 1.00
Level of education 0.69
Beyond college 0.92 (0.49–1.74)
College 0.78 (0.42–1.43)
High school or less 1.00
Poverty level 0.04
>500% of the poverty level 1.03 (0.18–5.79)
200–500% of the poverty level 0.48 (0.08–2.75)
<200% of the poverty level 1.00
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fied, we looked at cessation rates in subgroups 
that were defined by seven baseline variables: sex, 
income (<200%, 200 to 500%, and >500% of the 
federal poverty level), heavy smoking (≥2 packs per 
day) or nonheavy smoking, number of previous 
attempts to quit (0 to 2, 3 or 4, or ≥5), stage of 
quitting as defined by Prochaska et al.17 (precon-
templation, contemplation, or preparation), self-
assessed health (poor, fair, good, very good, or 
excellent), and nicotine dependence as assessed 
by the score on the Fagerström Test for Nicotine 
Dependence (<6 or ≥6). The homogeneity of the 
association (i.e., interaction) between the group 
assignment and cessation rates across subgroups 
was assessed with the use of the Cochran–Mantel–
Haenszel test. Within each subgroup, rates of ces-
sation in the incentive and control groups were 
compared with the use of chi-square tests.
Our power calculations were based on expected 
12-month cessation rates of 3.0% in the control 
group and 9.4% in the incentive group. To have 
80% power to show a difference between groups, 
with a 1% two-sided type I error, we needed to 
have 360 participants in each group; we increased 
that number by 15%, to 425 in each group, to 
account for loss to follow-up resulting from ex-
pected employee turnover. No interim analyses 
were planned or conducted. All reported P values 
are two-sided and were not adjusted for multiple 
comparisons.
R esult s
Figure 1 shows the numbers of subjects who were 
screened and who participated in the study inter-
vention and follow-up. Of the 1903 people who 
initially expressed interest in participating, 878 
(46%) were enrolled; 436 participants were ran-
domly assigned to the incentive group, and 442 
to the control group. Demographic characteristics, 
smoking behavior, degree of nicotine dependence, 
readiness to quit, and health status were similar 
in the incentive and control groups (Table 1). Par-
ticipants in both groups smoked approximately 
one pack of cigarettes per day, and approximately 
5 to 6% of the participants were heavy smokers. 
The majority of the sample had incomes that were 
greater than 500% of the poverty level, and ap-
Table 3. (Continued.)
Variable Odds Ratio (95% CI) P Value
Smoking status† 0.20
Heavy 0.38 (0.09–1.67)
Nonheavy 1.00
Previous attempts to stop smoking 0.09
≥5 (top third) 2.00 (1.08–3.71)
3 or 4 (middle third) 1.58 (0.81–3.06)
1 or 2 (bottom third) 1.00
Stage of change§ 0.10
Preparation 2.61 (1.02–6.62)
Contemplation 1.64 (0.71–3.83)
Precontemplation 1.00
Self-reported health 0.37
Excellent 1.85 (0.21–16.54)
Very good 1.14 (0.13–9.66)
Good 1.09 (0.13–9.37)
Fair 0.58 (0.06–6.08)
Poor 1.00
* Odds ratios for work-site groups are not reported, owing to the large number of sites included.
† Heavy smoking was defined as 40 cigarettes or more per day.
‡ One study participant was not included in this analysis, owing to missing data on race or ethnic group.
§ Stage of change refers to the smoker’s readiness to quit, as defined by DiClemente et al.16 and Prochaska et al.17  
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proximately 90% of the participants were white. 
A similar number of participants in the incentive 
and control groups were lost to follow-up or with-
drew in the first 6 months (66 and 59 participants, 
respectively; P = 0.45) and through month 12 (56 
and 47, respectively; P = 0.25).
The 9-month or 12-month rate of cessation, as 
confirmed by cotinine testing, was 14.7% in the 
incentive group, as compared with 5.0% in the 
control group (P<0.001) (Table 2). In both the in-
centive group and the control group, very few of 
the participants who reported that they had quit 
smoking did not submit samples for testing (0.5% 
and 1.1%, respectively), and no participants who 
submitted samples had positive test results. The 
rate of participation in a smoking-cessation pro-
gram was significantly higher in the incentive 
group than in the control group (15.4% vs. 5.4%, 
P<0.001), and a significantly higher percentage of 
incentive-group participants completed a smok-
ing-cessation program (10.8% vs. 2.5%, P<0.001). 
Members of the incentive group who participat-
ed in a smoking-cessation program had signifi-
cantly higher rates of cessation than did members 
of the control group who participated in such a 
program (46.3% vs. 20.8%, P = 0.03).
The cotinine-confirmed cessation rate within 
6 months after study enrollment was 20.9% in the 
incentive group, as compared with 11.8% in the 
control group (P<0.001). The cessation rate at 15 
or 18 months was 9.4% in the incentive group, 
as compared with 3.6% in the control group 
(P = 0.001). Among participants who had not 
stopped smoking in the first 6 months — and 
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Figure 2. Rates of Smoking Cessation in Various Subgroups at 9 or 12 Months.
Stage of change refers to the smoker’s readiness to quit, as defined by DiClemente et al.16 and Prochaska et al.17 
The Fagerström Test for Nicotine Dependence14 has a range of 0 to 10, with higher scores indicating greater nico-
tine dependence; a score of 6 or more was used to classify participants as highly dependent on nicotine.15
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thus were ineligible for financial incentives — 
the cotinine-confirmed cessation rates were simi-
lar in the incentive and control groups (4.1% and 
5.9%, respectively; P = 0.29).
The odds ratios for quitting by 9 or 12 months 
(Table 3) were significantly higher in the incen-
tive group than in the control group in the un-
adjusted model (odds ratio, 3.28; 95% confidence 
interval [CI], 1.98 to 5.44), in a logistic-regression 
model that adjusted for stratification variables only 
(odds ratio, 3.19; 95% CI, 1.91 to 5.30), and in a 
model that adjusted for all the variables included 
in Table 1 (odds ratio, 3.16; 95% CI, 1.88 to 5.32).
Exploratory Subgroup Analyses
Figure 2 shows 9-month or 12-month cessation 
rates stratified according to subgroup. For all sub-
groups, members of the incentive group had high-
er cessation rates than members of the control 
group. None of the tests for interaction showed 
significant differences in this population; in-
stead, the observed patterns showed a consistent 
effect of the intervention across numerous char-
acteristics.
Discussion
In this study of employees at a large corporation, 
rates of prolonged abstinence from smoking after 
9 or 12 months of follow-up were 14.7% in the 
group that was eligible for financial incentives and 
5.0% in the control group. Rates of prolonged ab-
stinence at 15 or 18 months in the incentive group 
remained significantly higher than those in the 
control group.
A 2005 Cochrane Collaboration review of fi-
nancial incentives for smoking cessation in work-
place settings concluded that there was insuffi-
cient evidence that these incentives are effective.11 
One reason for this finding may be that many 
previous studies were not designed with samples 
that were large enough to detect the differences 
we observed. A second reason may be that the in-
centives used in previous studies have generally 
been small (as little as $10 in some of them). Stud-
ies have shown that financial-incentive programs 
are associated with an increased rate of smoking 
cessation in the short term, but the programs re-
ported in these studies were not designed to fo-
cus on sustaining high rates over time.7,9 The re-
lationships of the size and structure of incentive 
payments to rates of smoking cessation remain 
important empirical questions that need to be 
addressed in future research. It is possible that 
larger — or smaller — payments by employers 
could be more cost-effective in improving smok-
ing-cessation rates. The optimal design of incen-
tive programs for smoking cessation is also an 
open question, since extension of the incentives 
beyond 12 months may result in higher cessation 
rates over a longer period.
The cotinine level, which we used for biochem-
ical verification of 7-day abstinence, is considered 
to be the best biomarker of smoking cessation.12 
Consistent with the recommendations of the So-
ciety for Research on Nicotine and Tobacco, our 
primary measure of self-reported cessation at both 
9 or 12 months and 15 or 18 months was pro-
longed abstinence.12 Although prolonged absti-
nence can be biochemically verified only indirectly 
because of the limitations of the cotinine test, it 
is likely that the point prevalence is highly cor-
related with prolonged abstinence 6 months after 
short-term quitting was assessed.12
To date, financial incentives within health care 
settings have been directed primarily toward pro-
viders, through Pay for Performance (P4P) pro-
grams. However, given that up to 40% of pre-
mature deaths in the United States are due to 
unhealthful behaviors such as smoking, poor di-
etary habits, and sedentary lifestyles,18 incentives 
directed toward patients rather than providers may 
have greater potential for changing health behav-
iors.19-21 One approach to encouraging smoking 
cessation would be to adjust health-insurance pre-
miums on the basis of smoking status; however, 
targeted payments for smoking cessation have the 
advantage of being unbundled from health-insur-
ance premiums and thus may be more salient to 
people, thereby having a greater influence on be-
havior.22
The financial benefit to employers of having 
their employees stop smoking is estimated to be 
about $3,400 per year23 as a result of increased 
productivity, decreased absenteeism, and a reduced 
incidence of illness. There is also strong evidence 
that employees prefer to work for firms that offer 
effective and attractive benefit programs.24 How-
ever, few employers offer full coverage of smok-
ing-cessation services or cessation programs in 
the workplace,8,25,26 partly because a compelling 
“business case” for such coverage has not been 
made. Notably, neither the financial-incentive in-
tervention nor the control intervention in our study 
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included the establishment of a smoking-cessa-
tion program; both interventions merely encour-
aged participants to use existing programs.
The literature on smoking cessation suggests 
that most relapses occur within the first month 
of cessation, that approximately 90% of relap-
ses occur within the first 6 months,27 and that 
the likelihood of continuous abstinence over a 
20-month period is about 95% for smokers who 
quit for 1 year or longer.12 Our finding of relapse 
rates between the 9- or 12-month visit and the 
15- or 18-month visit (27.3% in the control group 
and 35.9% in the incentive group) that appear to 
be higher than those reported in the literature 
may suggest that relapse rates differ according 
to whether smoking cessation occurs in the pres-
ence or absence of incentives. However, since the 
relapse rates in both the incentive and control 
groups differ from those in the literature, and in 
view of the relatively small number of partici-
pants in our study who quit smoking, we cannot 
be confident that the relapse rates do in fact dif-
fer from those previously reported.
Because approximately 90% of the enrolled 
population was white and the participants had 
relatively high education and income levels, our 
study may have limited generalizability to employ-
ees with lower socioeconomic status than that of 
the participants in our study or to members of a 
minority racial or ethnic group. In addition, pro-
grams that are designed to change behavior may 
have unintended consequences that we could not 
observe in our study. However, we think it is un-
likely that substantial numbers of people would 
start smoking in order to be eligible for such in-
centive programs. Studies such as this one are 
subject to selection bias, in that smokers who vol-
untarily enroll in these programs may be more 
likely (whether they are assigned to the incentive 
group or the control group) to quit smoking; it is 
difficult to project how effective these programs 
would be in a population that included all employ-
ees within a given company. 
In summary, this study shows that smoking-
cessation rates among company employees who 
were given both information about cessation 
programs and financial incentives to quit smok-
ing were significantly higher than the rates among 
employees who were given program information 
but no financial incentives.
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